text:
Creating an Economy of Need in Greece
by Leo Panitch May 31, 2015 September 23, 2020
Leo Panitch, professor of political science at York University, talks about the difficulties and tensions in running a state connected to people
SHARMINI PERIES, EXEC. PRODUCER, TRNN: Welcome to The Real News Network. I'm Sharmini Peries coming to you from Baltimore. I'm in conversation with Leo Panitch on Greece. Leo has just returned from Greece, where he has been in discussion with a number of colleagues and friends about the situation there. Leo is professor of political science at York University in Toronto. He is the author of the UK Deutsche book prize winner, The Making of Global Capitalism: The Political Economy of American Empire. Leo, thanks again for joining me. LEO PANITCH, PROF. OF POLITICAL SCIENCE, YORK UNIVERSITY: Hi, Sharmini. PERIES: So Leo, in our first segment we were describing the situation in Greece as enormous suspension at various levels. And whether the Greek government is able to sort of envision a new economy, and the possibility of developing an independent economy to the European Union is in question. So tell me a little bit more about your thoughts there. PANITCH: I think whether they're in or out, all the more if they're out, of course, becomes much more of a necessity. But whether they're in or out, what one would want from this type of radical left government is an orientation towards putting people back to work, above all. Yes, of course, bandaging them from the assault that they've been subject to by neoliberal austerity, but also a restructuring of the economy in a way where production is much more for use, is much more rational than the chaotic irrational economies that capitalism now throws up. That should apply whether they're in or out. And of course, the big question is, is this possible if you're in the European Union at all. Or does the European Union have neoliberalism in its DNA? I should say, if the latter's the case that's going to be a heavy thing to bear, because I think all of the radical left parties are committed to internationalism rather than nationalism primarily. Although they stand up for the dignity of the people in their country and they get elected for standing up for that, as Syriza did. The kind of thing I'm talking about requires a government oriented to animating economic conversion. If Greece were to reorganize its agriculture so it wasn't so heavily dependent on agricultural subsidies from Europe, and they do have mountains of peaches which rot every year because of those types of subsidies, what type of agricultural production would be more rational? PERIES: What did you mean by that? That it just rots–. PANITCH: That kind of thing is what I'm thinking about. What type of, type of planning, what type of economic planning right down to the community and local level right across Greece, would allow for investment in new forms of software production, new forms of wine production, new forms of design, furniture, et cetera, that could be both related to a more internally-oriented economic development, but also allow for innovative and competitive exports in these more productive arenas. PERIES: And do you think, Leo, that will require the government investing in these kinds of productive enterprises? PANITCH: Well, sure. I mean, some funds would be needed here. But the left needs to look at itself, in all of its criticism of other governments, and we on the left are very quick to criticize, of course, any backsliding on the part of even such a radical government. What are our capacities when we elect a government to generate the type of movement from below, not just in the form of making demands upon that government, but in the form of actually ourselves getting involved at a local level, at a regional level in the difficult, creative activity of building a different type of economy. One of the problems with the left, and this is certainly true of the highly politicized Greek left, is that they're very good, in social movements, in the sense of mobilizing for demonstrations against this or that policy, or demanding this or that progressive policy. That's not the same thing as the type of activity that's needed, that the social networks in Greece display. Where you take matters in your own hands and you start creating an economy of need rather than economy of profit. Now, in order to do that in a way, of course, that would put the 45 percent of young people who are employed, the 30 percent of people generally who are unemployed in Greece, back to work doing productive things, that of course would need some central planning, it would need investment coming from regional and the national government. The local government. All of which are horrifically strapped. And one of the terrible things about needing to produce a surplus in order to pay off some of the debt, as is being demanded by the institutions, as they're called, is that that money isn't going to that type of investment. But that's the kind of thing I think we should be asking ourselves. And one talks to people there and they don't know much about it. But what Roosevelt did with the Works Project Administration, the WPA, during the depressions lasted two years. A lot of Mount Rushmore was funded by sending people out to do that kind of work. Orson Welles' first play was funded under the WPA. Artists, filmmakers, et cetera. But in order to pull this off as well, one needs the type of animators, the type of organizers at the base who know something about production and who know something about economic life who are democratically-oriented, can mobilize people, who are able to sit down with the resources in a given community, both human and economic, and say, what can we do here that's new? This is the way we need to be thinking, I think. And that's true whether they're in or out, although I think the horizon in terms of what's possible were they to go out, even the Greek Syriza leadership imagines would be possible, would be broadened if there were more of that activity going on at the base. PERIES: And the ministries and some of your colleagues that you were speaking to has had roughly six months now to think about these strategies. PANITCH: [To this way], there are people in the party certainly, very impressive young people, who are oriented this way. Who are very senior in the party leadership and chose not to go into the government. People in the government are oriented this way. As I said, the Minister of Culture and Education who I know very well. He himself on a given day once a week simply announces that he's going down to a school. And he comes unaccompanied, and he talks to the teachers, and he sits in on parent-teacher meetings and on school events and plays. Sometimes even says, if you want me to give a–he's a philosopher. If you want me to give a talk on Greek history or Greek philosophy to the kids I will. And he says to the teachers' unions, we are committed to restoring collective bargaining. All labor rights have been taken away by the previous governments on the demand of the Troika. We are going to restore those. But you do need to realize that we don't have the money to pay you higher wages. That's not what we're about. You should be using this opportunity to change social relations using the schools in the community as the center of this. He says that. And one has to hope that will be taken up. Now, this is all very difficult. I mean, one of the fascinating things I watched at a public meeting was the deputy minister for social services, a remarkable woman who as a Syriza MP in the previous parliament had been crucial to creating the federation and solidarity networks known as Solidarity For All. And was the key person in coordinating them between 2012 to 2014. She said at this public meeting, I'm now finding when I want to talk to the people in the solidarity networks that I know so well, or they want to get to me, they need to go through a Syriza MP. And she said, I don't think that ought to be the role of the Syriza MPs. I mean, they ought to be of course mobilizing in the community and so on. But I don't think they ought to be just go-betweens between people in the community who I know and my ministry. And this produced a great deal of anger from the Syriza MPs who were at that meeting, young and old, male and female, who said, you're implying that we're going back to the old clienteleism. Of course they should be coming through us, of course we should be the ones who bring you the people in our community, et cetera. And what–it's not that one person's right, one is wrong. You see the incredible tensions and difficulties that are involved in figuring out how to run a state connected to the people in a different way. Above all, connected to activists in a way that's more creative than what usually happens in capitalist democracies, which is we elect an elite once every four or five years, and then they go off inside the state and cut themselves off from the movements that got them there. Even if they're a left government. So watching this is absolutely fascinating, and one has to say, I think, that the people who are doing this, whether they're MPs or ministers or party people at the base, need to be seen very sympathetically, because what they're trying to do is so momentous, so hard, and so important. PERIES: Leo Panitch, thank you so much for joining us, and we look forward to more reports from you. PANITCH: Good. Good to talk to you, Sharmini, again. PERIES: And thank you for joining us on The Real News Network.
DISCLAIMER: Please note that transcripts for The Real News Network are typed from a recording of the program. TRNN cannot guarantee their complete accuracy.


You may drive inside Tampere Exhibition and Sports Centre for the purpose of unloading or loading goods on every construction day except the last day before the exhibition opens. On the last day of construction you may drive vehicles inside the exhibition halls only to a specific loading area covered with protective carpets. There are trolleys available in this area.
You may drive vehicles inside the exhibition halls only to areas covered with protective carpets. Entering the halls with vehicles equipped with studded tyres is only allowed to the areas covered with protective carpets. Driving over the weight limit areas is forbidden. The areas are marked with plastic cones or other such signs, which are not to be moved.
Transportation vehicles and other vehicles may be kept in the parking area during the exhibition only in spaces designated for this purpose (exhibitors have their own parking area). Please notice that you must have a parking permit inside your car. Heavy vehicles may not be driven in the paved area close to the main entrance. Parking is also forbidden in that area.
Suomen Messulogistiikka Oy. You can order the forklift service on site at the exhibition office or via the doormen. The forklift service provider will invoice exhibitors after the event according to current price list.
Handling carts are available for moving lighter goods. Remember to book the forklift service for your suppliers if they are delivering goods to the venue.
You can start building your stand once you have paid the stand rent.
Ready-made stands are complete stand modules with structures, and they are suitable for those who want to have a very simple stand that they decorate themselves. The price of a ready-made stand includes wall elements, a blank fascia board, blue carpet, connections for electricity and lighting supply power and cleaning on trade fair days. A corner stand is open on the corner, unless otherwise agreed.
Ready-made stands will be completed in the hall on the last construction day at 8 am, after which you can start decorating your stand. If you require alterations or additional elements to your stand, you should order them in advance.
Any repairs, replacements or cleaning required for the exhibition structures or rented furnishings will be invoiced after the event if such damage is detected. Any tapes and glue applied must be removed after the event. Hooks are available in the Expotec Oy office that can be used to hang items on the walls without fixation.
Exhibitors must cover the entire floor of the stand with carpet. Carpets must be fire retardant (class L). Carpets may not be fixed directly onto the floor of the hall.
The stand must be fitted with wall elements on the sides that are adjacent to another stand or a technical space. If there is a technical service well in your stand, it must be surrounded with wall structures and access provided through a door or a curtain structure. Please note that each well is used to provide electricity, water and sewage connections to several stands. Unless otherwise agreed with the neighbouring stand, an exhibitor may not use the wall constructions set up by other exhibitors/the neighbouring stand.
Because of the automatic sprinkler system, stands may not have closed ceilings. The authorities will only approve latticework, grills and other open ceiling structures (permeability at least 50 %). Any fabrics used must be impregnated with a fire retardant (in flammability classification 1).
If any product requires a different kind of ceiling structure (for example tents and caravans), stand has to be provided with a fire extinguisher (size 6 kg). A plan including details of the structure and product must be submitted to the organiser 30 days prior to the exhibition. The organiser will negotiate the matter with fire authorities and inform the exhibitor in due course.
If you need to attach items on the walls and pillars in order to build or decorate your stand or present your product, you must agree on this with the organiser 30 days before the start of the event. The exhibitor is responsible for the costs and fixatives.
Suspensions from the ceiling are always carried out by a subcontractor authorised by the organiser. The subcontractor is responsible for the safety of the equipment in accordance with industrial safety legislation. Suspensions are possible only in certain locations in halls A, C, D and E. Suspensions are not possible in hall B.
The height of an extended suspension may be between 5 and 9 metres from ground. The price includes suspension equipment up to the determined height, where the exhibitor may fix their items. The exhibitor must order and pay for the suspension work from the organiser using a specific form. Detailed placing sketch and specifications must be included in the suspension plan. The information must be submitted to the organiser 30 days before the start of the event. The event organiser will approve the suspension plan, check whether suspension is possible in the desired location, and deliver the information and order to the subcontractor. The subcontractor will invoice the exhibitor directly.
The standard/minimum height of the exhibition structures is 250 cm. All wall and decoration solutions exceeding this height are subject to the organiser's advance permission. Placing sktech must be submitted to the event organiser 30 days before the start of the event.
Structures exceeding the standard height must be placed at least one metre from the neighbouring stand. In case structures exceeding the standard height are placed closer than one metre from the neighbouring stand, permission must be obtained from the neighbouring exhibitor. Structures exceeding 250 cm are considered additional advertising space and invoiced after the fair.
Plans for two-storey structures, including strength calculations, must be submitted to the event organiser in three copies 30 days prior to the exhibition. The structure must be approved as a two-storey structure. When planning the stand, you should consider that two-storey structures must be placed at least two metres from the neighbouring stand.
In case the 2nd storey is intended for people, the storey must be outfitted on all sides with solid walls or railings, conforming to building regulations. The minimum height of the railing is one meter (1 m). The fee charged for the second storey area is 50 % of the standard fee per m2. The ground-level space covered by the upper floor must be equipped with a smoke detector and a 12 kg hand extinguisher.
You can place a fascia on the front of your stand with your company name and/or logo. The event organiser has the right to attach the stand number and corridor marking, including a number, a letter or another symbol, to the fascia.
Messusähkö Oy supplies power connections and electric installations within the exhibition area. If, however, the exhibitor connects his own equipment into the electrical network installed by Messusähkö Oy, he is obligated to use only equipment approved in Finland, and to comply with electrical safety regulations. Please note that the installation ordered by the exhibitor is confined to the stand and must not exceed the power ordered for the stand. For example, 1 kW power is enough for a computer terminal and 2–4 100W lamps.
If the exhibitor has e.g. valuable and/or delicate data appliances at the stand, he must see to their protection himself. Note that valuables should not be left unattended at any time.
If you intend to paint in the exhibition area, you must cover the floor and the surrounding area. Painting equipment must not be cleaned in the toilets and maintenance rooms. Exhibitors are responsible for the appropriate disposal of paint waste, empty containers and equipment.
If you house a vehicle at your stand indoors outside fair opening hours, make sure that the main power switch is turned off or the battery cables disconnected. There may be fuel in the vehicle's tank.
The use of open fire is forbidden. Any devices in which the fire or flame burns outside the device, such as gas stoves, cookers, oil lamps, candles and other such items are considered open fires. A special permit can be granted if the demonstration in question is welding, gas cutting, cutting or other such method causing sparks. The application must be submitted to the organiser, complete with operation and safety structure plans 14 days prior to the fair. The permit will always be negotiated with fire and rescue authorities.
There is no permanent location for working with fire in the exhibition halls. A permit is required for all work with fire in the halls. The permit for working with fire is granted by the Technical Manager of Tampere Trade Fairs Ltd.
A personal license for working with fire is required from each person actually working with fire. As to working with fire, the safety regulations for Working with fire and Working with fire on roof are to be followed.
The technical and service rooms in the halls must not be used for storage.


Bob Donald has more than 13 years of experience designing and building standalone applications, client/server applications, and enterprise applications. He is a proponent of the use of UML during the analysis and design phases of software development and has broad experience working with various languages, such as Visual Basic, Visual C++, and Java. Bob has also been a guest speaker at the Connecticut Object Oriented Users Group, Microsoft TechNet, and in the Boston area COM Users Group. At ArsDigita, Bob is currently engaged in the architecture and design of their new collaborative workspace enterprise application.


text:
Lothar Kobluhn (12 April 1943 – 21 January 2019) was a German professional footballer who played as a midfielder. Kobluhn, who was playing for Rot-Weiß Oberhausen at the time, was the Bundesliga's top scorer in the 1970–71 season, scoring 24 goals. Kobluhn had to wait 36 years for the top scorer trophy to be awarded because his club at the time, Rot-Weiß Oberhausen, was involved in the Bundesliga scandal. He finally received his award in 2007.

Kobluhn later played for SG Wattenscheid 09.

He died on 21 January 2019, aged 75. His elder brother  was also a footballer.

References

1943 births
2019 deaths
German footballers
SG Wattenscheid 09 players
Rot-Weiß Oberhausen players
Bundesliga players
2. Bundesliga players
Association football midfielders
Sportspeople from Oberhausen
Footballers from North Rhine-Westphalia
West German footballers

redpajama_set_name: RedPajamaWikipedia


Because few of its new patients miss an appointment, largely because they don't want to go to the back of the multi-month waiting list, Ms. Boling's group doesn't overbook first visit slots. Also, it doesn't overbook their nurse practitioners, reserving them for same-day appointments for a sudden flair or other complaint.
Computerization of scheduling has made it easier to start and maintain waiting lists. When last-minute cancelations or no-shows occur, people on the list are contacted until the spot is filled.
The final option is discharging the patient from the practice. Those interviewed all agree this is used only after multiple missed appointments and specific and ongoing follow-up communications.
The general consensus is that a contact is made after the first no-show, asking the patient to get in touch and reschedule. The second puts them on probation, and they are told three could result in being discharged. If another appointment is missed, then the attending physician is contacted, and they make the termination decision.
Kurt Ullman has been a contributing writer to The Rheumatologist for 10 years.
The Sentara Medical Group in Virginia has taken a different tack for its no-show problems.


text:
Keys to Diversifying Your Workplace
In a new report, TalentRISE offers six approaches to bringing diversity to your company's C-suite. Employment branding, leveraging public relations, and embracing diverse thoughts and experiences into hiring strategies are among the suggestions that can change your organization for the better.
August 15, 2022 – It is by now widely known that diversity and inclusion are good for business—especially for high-powered companies. When considering high-quality candidates for new C-suite positions, what are some policies, procedures, or practices that business leaders can implement to diversify their hires? To answer this question, Carl Kutsmode, SVP of talent consulting and executive search at TalentRISE, recently reported on the subject in an online post.
According to Mr. Kutsmode, there are at least six good ways to diversify the C-suite:
1. Invest in employment branding to highlight diversity in your organization.
"This is how to attract the best DEI leaders and staff," said Mr. Kutsmode. "Also consider creating tailored job applicant experiences for different target talent groups. From there, ensure that those messages, images, etc. are representative of the diversity you seek to attract (and currently have)."
2. Use video to tell your story of being an inclusive organization.
Why tell people your employees bring their best and whole self to work when you can show them? "Video is 55 times more search engine optimized and will be shared more than text content by job candidates who resonate with the content," said Mr. Kutsmode. "Tools like SparcStart, Hinterview, and Digi-Me offer turnkey video creation tools to enhance your brand and share your message using video."
3. Leverage the power of PR.
Get your leaders who represent various diverse groups in the media—and don't forget to represent members of the LGBTQ, military, or differently abled communities, according to Mr. Kutsmode. "Your leaders should be speaking on hot trends while representing your brand, sharing their vision for your company, and highlighting your company's key selling points making it a great place to work," he said.
4. Embrace and incorporate diverse thoughts and experiences into hiring strategies.
Mr. Kutsmode notes that hiring managers tend to get stuck on requiring new hires to come from within their industry when, in many cases, their industry lags in adopting leading-edge best practices. With this mindset, these leaders cut off many well qualified people from progressive and forward-thinking industries who can bring fresh perspectives, ideas, and proven solutions to challenges they encounter in their role.
5. Have a formal diversity recruitment strategy and goals.
Your diversity strategy should include promoting diverse talent from within in addition to hiring diverse talent from outside your company. "Clearly communicate and track progress against your diversity hiring goals," said Mr. Kutsmode. "Appropriately (and selectively) share your results and progress internally and externally so that talent in the marketplace can see you are committed to DEI and putting action behind words. This will help you attract employees who seek to leave a company that lives in a 'check the box' diversity compliance culture."
6. Become a recognized destination employer that diverse talent wants to work for.
Consider submitting applications to qualify for the Forbes, Fortune, and Diversity Inc. annual list of top diverse employers to work for lists and other similar awards. Then use them in your recruitment advertising and branding efforts if you make their list as a winner.
Challenges Facing Women
While great strides have been made in placing women in leadership positions, they still experience challenges that men don't while attempting to advance their careers in companies, on boards, and in government, according to a separate report from Pete Petrella, executive search practice leader at TalentRISE. The U.S. has a multitude of college-educated women who are qualified to fill leadership positions but yet they still face barriers on their way to the top.
What to Ask Yourself Before Making a Diversity Hire and How Data Can Help
There are encouraging signs that diversity, equity, and inclusion is becoming a key factor for companies looking for new talent. Challenges remain, however. In a new report, Odgers Berndtson suggests that businesses ask three key questions early on to improve their efforts: Where are you on your DEI journey, really? How will you support diverse hires once they're on board? And why are you making a diverse hire in the first place?
According to a recent Society of Human Resource Management (SHRM) report, women experience challenges that their male counterparts don't when attempting to advance their careers. Nine percent of HR professionals describe their organization's leaders as predominantly women, whereas 50 percent describe their organization's senior leaders as predominantly men. Only 61 percent of women say their manager encourages them to grow their career compared to 71 percent of men.
White female managers (65 percent)—and especially female managers of color (57 percent)— are less likely to feel included in key networks at their organization than male managers of color (68 percent) and white male managers (73 percent).
Related: What to Ask Yourself Before Making a Diversity Hire and How Data Can Help
Female managers with caregiving responsibilities (35 percent) are more likely to have experienced a pandemic-related career setback than their male counterparts (26 percent).
Barriers Women Face
Over the past several decades, women have overcome multiple barriers in the workplace, but still, hold only 21 percent of C-suite positions. Below are some barriers they face that continue to delay and challenge their progress:
Structural: "When they lack access to established professional networks, women face structural barriers," said Mr. Petrella. "Women are less likely to be invited to social activities where they can interact with a network of colleagues that can assist them in advancing their careers."
Institutional: Gender stereotyping results in unequal and unfair treatment toward women. Institutional barriers—such as stereotypes that portray brilliance as a male trait—hold women back from a wide range of prestigious careers research conducted by scientists at New York University, University of Denver, and Harvard University has shown.
Personal mindset: Women are often their own biggest critics. Lack of confidence and risk aversion frequently hold them back from seeking leadership positions, according to Mr. Petrella. "Because of this, many women have opted to work for private sector, non-profit, or start-up companies where there are more female owners, leaders, and employees," he said.
Lifestyle: Caregiver priorities often contribute to the gender gap. According to the TalentRISE report, when a woman is the primary family breadwinner, she's usually also the primary caregiver. In comparison, when a man is the primary family breadwinner, he is not usually the primary caregiver, too.
What your organization can do to attract and retain women for leadership roles?
A Pew Research Center Social and Demographic Trends survey found that women are better than—or equal to—men in seven of the eight primary leadership traits (honest, intelligent, hardworking, decisive, ambitious, compassionate, outgoing, and creative). Companies must make intentional efforts to attract and retain women for leadership roles.
Support female leaders: "To support the female leaders within your organization, ensure your offering mentorship, professional networking, and development opportunities for all employees," Mr. Petrella said.
Identify hidden biases: HR leaders must consider every worker qualified for a position and make sure that all skilled employees are offered equal opportunities.
Develop a DEI&B strategy: "To attract and retain women talent for leadership roles, be sure to develop a diversity, equity, inclusion, and belonging strategy that's data-driven to track your progress and identify gaps," said Mr. Petrella.
Workplace diversity increases creativity, brings unity to teams, and transparently displays equal opportunity, according to Mr. Petrella. "When women thrive in leadership roles, organizations benefit from increased productivity and greater innovation," he said. "Companies that don't work to create an inclusive leadership environment—with equitable opportunities for all employees—will face challenges in attracting and retaining their top female talent."
Related: The Importance of Setting Proper Diversity Targets
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media
Tags: DiversifyingKeysworkplace
Editorial Roundup: Nebraska
Pitch competition celebrates a decade of innovation and entrepreneurship | Queen's Gazette
Pitch competition celebrates a decade of innovation and entrepreneurship | Queen's Gazette

redpajama_set_name: RedPajamaCommonCrawl


2016 Subaru Xv Crosstrek Release Date Uploaded by admin on Monday, October 19th, 2015 in category Uncategorized.
See also 2016 Subaru Xv Crosstrek Turbo from Uncategorized Topic.
Here we have another image 2016 Subaru Xv Crosstrek News featured under 2016 Subaru Xv Crosstrek Release Date. We hope you enjoyed it and if you want to download the pictures in high quality, simply right click the image and choose "Save As". Thanks for reading 2016 Subaru Xv Crosstrek Release Date.


text:
Advancing peer review
Standards and affiliations
Partnerships and societies
Publication costs and funding
OA funding and policy support
Scientific press releases
Longer hours on social media may increase teens' risk of cyberbullying
Cyberbullying may be linked to higher use of social network sites by school children aged 14-17 years, rather than to simply having a social network profile, according to a study published in the open access journal BMC Public Health, which examined data from several European countries.
Researchers at the National and Kapodistrian University of Athens, Greece found that school children in Romania, Germany and Poland were more likely to experience cyberbullying, such as aggressive and threatening messages, social exclusion, spreading rumors and sharing private, inappropriate or humiliating information, if they used social network sites for more than 2 hours a week day.
Co-author Professor Artemis Tsitsika said: "This is an important finding which challenges past research suggesting that simply having, rather than excessive use of, a social network site profile increases the risk of becoming a victim of cyberbullying."
The researchers found that a relatively high proportion of school children in Romania (37.3%), Greece (26.8%), Germany (24.3%) and Poland (21.5%) have been bullied online whereas a fewer proportion experience cyberbullying in the Netherlands (15.5%), Iceland (13.5%) and Spain (13.3%).
Professor Artemis Tsitsika added: "We found multiple factors, in addition to the time spent on social media, which may impact cyberbullying frequency and explain the differences between countries. In Greece and Romania higher cyberbullying may be due to a lack of digital literacy and relevant legislation, as well as sudden rise of social media use and a large technological gap between parents and the younger generation. Promotion of internet safety strategies and teaching digital skills in education may contribute to lower rates of cyberbullying in the Netherlands. In all cases higher daily use with no monitoring and digital literacy background may lead to teenagers posting private information and meeting strangers online".
The researchers call for educational settings to integrate ICT education into their curricula, especially in countries where use of the Internet has risen abruptly.
The authors undertook a school-based study across Germany, Greece, Iceland, the Netherlands, Poland, Romania and Spain. Anonymous questionnaires about internet use, social factors and cyberbullying were completed by 12,372 students aged 14 – 17 across the seven countries.
They caution that the observational nature of the study limits conclusions about the direct causes of cyberbullying. As five years have passed since the data used in the study was collected, its ability to represent the current picture of cyberbullying may be limited.
Media Contact
Hannah Lewis
Communications Assistant
T: +44 2078 4336 24
E: hannah.lewis@biomedcentral.com
Notes to Editor:
1. Research article:
Cross-national aspects of cyberbullying victimization among 14–17-year-old adolescents across seven European countries.
Athanasiou et al. BMC Public Health 2018.
The article is available at the journal website.
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BMC's open access policy.
2. BMC Public Health is an open access, peer-reviewed journal that considers articles on the epidemiology of disease and the understanding of all aspects of public health. The journal has a special focus on the social determinants of health, the environmental, behavioral, and occupational correlates of health and disease, and the impact of health policies, practices and interventions on the community.
3. A pioneer of open access publishing, BMC has an evolving portfolio of high quality peer-reviewed journals including broad interest titles such as BMC Biology and BMC Medicine, specialist journals such as Malaria Journal and Microbiome, and the BMC series. At BMC, research is always in progress. We are committed to continual innovation to better support the needs of our communities, ensuring the integrity of the research we publish, and championing the benefits of open research. BMC is part of Springer Nature, giving us greater opportunities to help authors connect and advance discoveries across the world.


text:
Queens Man Charged With Kidnapping & Raping Ex-Girlfriend
Modified Aug 16, 2015
A 21-year-old Queens man has been arrested after he allegedly kidnapped his ex-girlfriend at knifepoint and raped her during a nine-hour ordeal this weekend.
According to police, the harrowing incident got started when suspect Jonathan Coronel ran into his 18-year-old ex near a shoe store on the corner of 81st Street and Northern Boulevard around 9:30 a.m. on Saturday. The victim ran into the store after seeing Coronel, whom she had a restraining order against. Coronel followed her inside, took out a knife, and forced her to get into his car.
Witness Kalandrov Mosshilov told the News that Coronel was waving the knife in his face when he tried to stop him.
"A guy followed her into the store," Anada Krishna, who lives above the shop, told the News. "I hear the guy tell her, 'Give me my money! Give me my money!'"
Over nine hours later, cops say Coronel dropped the victim off around 9:40 p.m. at the corner of 82nd Street and Astoria Boulevard, a few blocks away from her Elmhurst home. The suspect was taken into custody at 88th Street and 24th Avenue a few hours later. He was taken to Elmhurst Hospital with a self-inflicted stab wound to the torso and is currently listed in stable condition.
He has been charged with kidnapping, rape, robbery, criminal possession of weapon, unlawful imprisonment and criminal contempt.
jonathan coronel


text:
Foundations, Policy
The LIVESTRONG Silent Type
Mike Keefe-Feldman
October 11, 2012; Source: Agence France-Presse
This week, the U.S. Anti-Doping Agency released its files related to its doping charges against Lance Armstrong. The NPQ Newswire has been following the impact of the doping charges against Armstrong on his foundation (see here and here). So far, that impact hasn't been large and the Lance Armstrong Foundation, also known as LIVESTRONG, has been able to sidestep the issue, focusing instead on its valuable cancer work rather than the controversy surrounding its titular leader. Now, however, some are suggesting that may become harder to do.
As Agence France-Presse (AFP) puts it, "[G]iven that a Google news search using the terms 'Lance Armstrong' and 'doping' was generating 51,400 hits at 1500 GMT on Thursday, the appetite for the story may soon envelop the charity, and require a more aggressive response." AFP also cites Chris Edwards, the owner of Reputation Saviors, a company that focuses on battling bad press on the Internet, who reportedly feels, in AFP's words, that "if attention moves to the charity's own actions, they will have no option but to reply." At least for now, though, the Lance Armstrong Foundation, isn't doing so.
No one that we're aware of is suggesting that Armstrong's alleged doping reflects in any way upon the work of LIVESTRONG. Rather, Edwards argues that "when the entire news media starts to report something it is [a] very difficult situation to combat" and that "if that happens to LIVESTRONG they will have to do something. You can't just not answer back." If that's so, then the foundation's problem isn't just about Lance Armstrong. It's also about a scandal-hungry media culture. Neither concern is something that the foundation can do anything about, really. But let's not pretend that when such scandals hit, they are solely the doing of one celebrity actor; media outlets are an active participants in this ugly game. Let's hope that all the good work of LIVESTRONG doesn't become the collateral damage of a 24/7 infotainment cycle. –Mike Keefe-Feldman
Video Game-Linked "Digital Telethons" Emerge as Fundraising Tool
Public Catches On to Megadonor Domination over Philanthropy—and Everything Else
Coldplay Seeks to Make Its Tours Carbon Neutral
By Marian Conway
Nonprofit-Municipal Relations Go Awry in a Small Florida City
A Nonprofit-Corporate Alliance Goes Horribly Wrong in a Preventable Way
Standing Up Warren Buffett on his Charity Lunch
Welcome to the New Facebook…Now Buy Something
By Aine Creedon and Mike Keefe-Feldman
$500 Million Pledged at Concert in NYC's Central Park
By Mike Keefe-Feldman
Direct Mail Firm "Masterminds of Money Laundering?"


text:
Курунг-Кюеле — топоним в России якутского происхождения. В основе лежит географический термин , передаваемый как «кюеле/ кюёле/ кюель/ кюёль», со значением «озеро», «озёрный».

Республика Саха (Якутия)
 Курунг-Кюеле — озеро, в левобережье р. Берге-Тюгюэне, координаты 63°39' с. ш. 127°02' в. д.
 Курунг-Кюеле — озеро, в левобережье р. Ханчылы, координаты 63°19' с. ш. 128°28' в. д.
 Курунг-Кюеле — озеро, в левобережье р. Матта, координаты 62°06' с. ш. 126°57' в. д.
 Курунг-Кюеле — река, правый приток р. Арга-Сала, координаты 65°24' с. ш. 120°08' в. д.
 Курунг-Кюеле — урочище, южнее озера Орто-Кюель, координаты 64°27' с. ш. 119°39' в. д.
 Курунг-Кюеле — озеро, между р. Кылыяр и р. Эбиет-Юрюете, координаты 67°39' с. ш. 134°59' в. д.
 Курунг-Кюеле — озеро, между р. Лена и р. Бахынай, координаты 65°50' с. ш. 123°51' в. д.
 Курунг-Кюеле — озеро, на левом берегу р. Сюдюнгде-Сяне, северо-западнее озера Мюлюре, координаты 65°52' с. ш. 121°48' в. д.
 Курунг-Кюеле — озеро, в истоке р. Шапка, на левом берегу р. Джарджан, координаты 68°41' с. ш. 125°25' в. д.
 Курунг-Кюеле — озеро, в правобережье р. Чюэлю, координаты 63°31' с. ш. 126°57' в. д.
 Курунг-Кюеле — озеро, на правом берегу р. Буор-Сала, координаты 68°45' с. ш. 139°08' в. д.
 Курунг-Кюеле — озеро, между р. Бысыттах и р. Уэль-Сиктях, координаты 69°19' с. ш. 125°10' в. д.
 Курунг-Кюеле — озеро, западнее оз. Байкал, координаты 68°45' с. ш. 151°17' в. д.
 Курунг-Кюеле — озеро, в правобережье нижнего течения р. Хомпу, координаты 61°30' с. ш. 130°50' в. д.
 Курунг-Кюеле — озеро, на правом берегу р. Кумах-Юрях, координаты 62°23' с. ш. 122°34' в. д.
 Курунг-Кюеле — урочище, между р. Сэтэкэ и р. Умулун, координаты 63°25' с. ш. 120°26' в. д.

См. также
 Курунг-Кюель

Примечания


Together with Lang Lang and Yundi Li, Sa Chen (born 1979) is considered as one of today's most important Chinese pianists and a veritable international sensation. Originally a student of Professor Dan Zhao, China's most eminent piano teacher, she won first prize in the 1994 China International Piano Competition and fourth place in the 2000 International Frederick Chopin Piano Competition in Warszaw and a prize in the Leeds International Piano Competition.
Furthermore, she was a third place winner in the 2005 Van Cliburn International Piano Competition. She has continued her training with Joan Havill in London and Arie Vardi in Hannover where she now resides.
Here we can hear her in the second movement of Chopin´s first Piano Concerto in E minor Op. 11 with the Gulbenkian Orchestra, Lisbon conducted by Lawrence Foster.
What more can I say but 'spell-binding'!
This young woman feels the music and is great at making you feel it.
She is spiritual with her music.
É um fenômeno que os asiáticos, detentores de cultura multililenar, voltem-se para assimilar a música ocidental e o façam com tal Arte e expresividade que nos deixae, simultaneamente, maravilhados e curiosos: como e por que isto acontece?


avirafree.xyz 9 out of 10 based on 380 ratings. 730 user reviews.
Avira 2019 Mobile Security For Android Free Download is really a fantastic choice for people who want a no-nonsense antivirus security suite with very few extras. The business certainly features a entire roster of solutions and features including a software updater, password manager, VPN, and system analyzer. However, Avira 2019 Mobile Security For Android Free Download focuses on its antivirus offerings first. Antivirus Pro-the subject of this review-is its main product for house users.
Like its competitors, Avira 2019 Mobile Security For Android Free Download has an "ultimate" package called Prime that offers all its goods for a single price. It is fairly pricey, nevertheless, at $120 to $156 per year based on how numerous devices you need to license.
Avira 2019 Mobile Security For Android Free Download is far cheaper by comparison at just $45 per year for five devices, with assistance for Windows, Mac, and Android. At that cost, Avira is fairly basic antivirus protection, with no extras. In fact, some customers might wonder why they should spend for Avira Pro over the company's free antivirus providing.
Get award-winning antivirus protection that runs silently within the background to secure your information, shield your privacy, and keep your Pc malware-free.
It is simple to make use of - just download and set up, then sit back and relax… you're protected for life! And it is fast and light, so it does not slow down your browsing encounter.
- Protects against dangerous web sites, blocks browser trackers for better internet privacy, and has a cost comparison tool for finding offers from trusted websites whenever you shop online (all included within the totally free internet browser extension).
Germany-based Avira knows security: Avira Free Antivirus shares exactly the same core technology as Avira 2019 Mobile Security For Android Free Download, named "2016 Item from the Year" by AV-Comparatives. Other independent antivirus reviews typically place it among the top antivirus software program accessible - which implies that your look for the very best free antivirus software program is more than!
Avira's protection-cloud AI technology gives you not just a real-time malware scanner and virus detector, but additionally an early warning method, which analyzes unknown files in the cloud - anonymously - from millions of users, to protect you from threats as they emerge in genuine time.
Avira is deemed a leading performer by third-party security testing firms. A-V Test said Avira had a 99 % detection rate for 0-day and malware attacks based on 202 samples. Malware detection, meanwhile, was at 100 % based on more than ten,000 samples.
A-V Comparatives found similar outcomes with 100 percent within the real-world protection tests, and 99.9 percent in its malware test. It was also very great within the firm's offline malware test detecting 98 percent of the almost 38,000 samples.
In our PCMark eight benchmark test, our test Computer scored the usual two,538 without any anti-virus installed, and two,533 with Avira operating. The larger quantity is better, which means Avira brought on a really minor drop in overall performance.
Within the Handbrake test, Avira brought on a slowdown of about 45 seconds within the encoding performance of a three.8GB HD video file. Usually, the test Pc can total that job having a fresh Windows ten set up in one hour, 15 minutes, and 30 seconds. With Avira operating, that time went as much as one hour, 16 minutes, and 13 seconds. Again, extremely minor influence for house customers.
Avira 2019 Mobile Security For Android Free Download offers fantastic antivirus protection, but should you spend $45 for it? You definitely get value compared to similarly priced A-V suites. The difficulty is that Avira's free option is not that various from the paid version. The only thing you don't get is the USB important warning (of arguable value), and web and mail protection.
If you don't use a mail desktop client, the mail protection isn't a lot use, and internet protection may be covered by a handful of totally free browser extensions alongside a contemporary browser.
In the event you need mail protection and/or you like the idea from the USB important warning, then Avira is a great choice. Otherwise, I'd suggest you attempt out the totally free version and see if you're missing anything.


Its cutting-edge and interdisciplinary approach to postgraduate learning, independent study, and life skills provides you with the analytical skills, conceptual knowledge and practical understanding of the real and imagined shifts that are taking place in – and through – the media industries, everyday life online and on the ground at home and abroad.
The Masters attracts budding scholars, media practitioners, activists, and advocates from many regions, with a variety of educational and professional backgrounds.
It's particularly suitable for those wanting to move their knowledge and analytical skills up a level for further study as well as for those who have experience of studying or working in the media and cultural sectors, non-profits and other third sector organisations, alternative media, the arts, grassroots and international advocacy and activism.
The Programme Director is Professor Marianne Franklin. Lecturers, guest speakers, and research students on this programme are affiliated to the Centre for the Study of Global Media and Democracy, the School of Mass Communications at Texas Tech University (USA), the United Nations Internet Governance Forum, Edinburgh Law School, Le Monde diplomatique, a number of international NGOs, activist and advocacy groups, international academic and media networks.
The themes covered may vary from year to year, depending on research developments and staff availability.
Along with two compulsory (core) modules, research skills module, and a research dissertation, you can choose from a range of theory and practice option modules from Media & Communications as well as other Goldsmiths departments.
Activities: Based on an interactive communication model of learning and teaching, the core programme is organised around lectures, participatory workshops, student presentations, written work, informed debates.
It features guest speakers from around the world and various media and communications domains.
It involves students in creating their own media-based projects, such as our prize-winning live Video Conference event with international partners.
It looks to foster original research dissertation work, formal presentation and collaborative skills.
On completing this programme you will be able to (re)enter the workplace, return to your creative pursuits, activism, or advocacy project or, if you wish, continue onto further research with up-to-date knowledge about the facts and fictions around these trends.
By term's end students will be fine-tuning their individual research projects, contributing to our study of these themes in class presentations. Workshops and one to one supervision will provide further support for students until the end of the summer teaching term.
We offer a wide range of option modules each year. For more information, please refer to our list of Media modules that are currently running.
Individual and group presentations; live video/web conferences, examined essays and research papers; qualitatively assessed assignments and discussion leading; dissertation.
We accept applications from October of the previous academic year through to September of the year for which you are applying. However, if you're applying for funding, you may be subject to an earlier application deadline (for example, for AHRC funding). If you are applying for a Chevening Scholarship you will need an unconditional offer to this programme in good time. Applications received by these deadlines are guaranteed consideration; we will consider later applications on a case by case basis.
Find out about staff in the Department of Media, Communications and Cultural Studies.
Alumni have found work with the BBC world service, Globo corporation, Carnegie Foundation, European parliament and European Commission, CCTV, NBC, Google, Microsoft, NGOs (eg Greenpeace, Global Partners) and charities (eg Dementia UK), newspapers (eg in South Korea, Brazil, Slovenia, China), alternative media and advocacy networks, museums, theatres and art gallerires, online national and international media outlets (eg Chinese, indigenous Taiwanese), PR and marketing around the world.
Other alumni have continued on to PhD programmes, at Goldsmiths and elsewhere. Many have been successful in gaining research scholarships and funding to further their academic and practitioner careers.
The ethos of the department is one which looks to achieve a healthy balance between scholarly pursuits and practical skills; we look to develop all-round thinkers and doers who can – and do – contribute to the cultural and professional life of their communities and countries. Graduates from this programme excel in their analytical skills, range of knowledge, flexibility, and adaptability.
At Goldsmiths we support and develop students to express themselves creatively and self-critically in theoretical, creative, practical and/or professional pursuits.
You will be equipped with new insights and ideas, analytical skills and practical knowledge about how both traditional and newer media, familiar and cutting-edge information and communication technologies, and computer-mediated communications actually operate and contribute to society, culture, and politics in contemporary settings.


The Summer Breeze Dress is a beautiful draping gown made in a soft cotton, with a relaxed fit and a batwing sleeve. The dress is detailed with delicate embroidery lace and intricate trims. An easy wear drawstring waistband with a tassel tie, this is definitely a statement piece that will have you feeling ultra feminine for your next Caribbean cruise.


text:
Q: cudaGetDeviceCount returns error: 1 invalid argument Running this code:
int device = 0;
cudaGetDevice(&device);
cudaDeviceProp props;
cudaGetDeviceProperties(&props, device);
const int kb = 1024;
const int mb = kb * kb;

cout << "Module Start:" << endl;
cout << props.name << ": " << props.major << "." << props.minor << endl;
cout << "  Global memory:   " << props.totalGlobalMem / mb << "mb" << endl;
cout << "  Shared memory:   " << props.sharedMemPerBlock / kb << "kb" << endl;
cout << "  Constant memory: " << props.totalConstMem / kb << "kb" << endl;
cout << "  Block registers: " << props.regsPerBlock << endl;
cout << "  Warp size:         " << props.warpSize << endl;
cout << "  Threads per block: " << props.maxThreadsPerBlock << endl;
cout << "  Max block dimensions: [ " << props.maxThreadsDim[0] << ", " << props.maxThreadsDim[1] << ", " << props.maxThreadsDim[2] << " ]" << endl;
cout << "  Max grid dimensions:  [ " << props.maxGridSize[0] << ", " << props.maxGridSize[1] << ", " << props.maxGridSize[2] << " ]" << endl;
cout << endl;

Results in the following garbage output and crash on RTX 2060, x64 Windows 10 on friend's computer:

EDIT:
I added some error checks:
int devicesCount;
cudaError_t error_id = cudaGetDeviceCount(&devicesCount);

if (error_id != cudaSuccess) {
    printf("cudaGetDeviceCount returned %d\n%s\n", (int)error_id, cudaGetErrorString(error_id));
    return 1;
} else {
    printf("Found %d GPUs\n", devicesCount);
}

and this is the error:
cudaGetDeviceCount returns error: "return 1, invalid argument"
It also appears he is using Windows insider edition and Driver Version 465.21, which is newer than the current stable release.
Works on the 1070, x64 Windows 10:

I tried using this post to get and set the active device, but that gave the same garbage output.
I am compiling to a .DLL and calling the functions through Python. It is possible that my Visual Studio project settings got messed up somehow, because it was working on friend's 2060 before.
"C:\Program Files\NVIDIA GPU Computing Toolkit\CUDA\v11.2\bin\nvcc.exe" -gencode=arch=compute_35,code=\"sm_35,compute_35\" -gencode=arch=compute_37,code=\"sm_37,compute_37\" -gencode=arch=compute_50,code=\"sm_50,compute_50\" -gencode=arch=compute_52,code=\"sm_52,compute_52\" -gencode=arch=compute_60,code=\"sm_60,compute_60\" -gencode=arch=compute_61,code=\"sm_61,compute_61\" -gencode=arch=compute_70,code=\"sm_70,compute_70\" -gencode=arch=compute_75,code=\"sm_75,compute_75\" -gencode=arch=compute_80,code=\"sm_80,compute_80\" -gencode=arch=compute_86,code=\"sm_86,compute_86\" --use-local-env -ccbin "C:\Program Files (x86)\Microsoft Visual Studio\2019\Community\VC\Tools\MSVC\14.28.29333\bin\HostX64\x64" -x cu   -I./ -I../../common/inc -I./ -I"C:\Program Files\NVIDIA GPU Computing Toolkit\CUDA\v11.2\/include" -I../../common/inc -I"C:\Program Files\NVIDIA GPU Computing Toolkit\CUDA\v11.2\include"     --keep-dir x64\Release  -maxrregcount=0  --machine 64 --compile -cudart shared --threads 0   -DWIN32 -D_MBCS -D_WINDLL -D_MBCS -Xcompiler "/EHsc /W3 /nologo /O2 /Fdx64/Release/vc142.pdb /FS   /MD " -o x64/Release/gpu_compute.cu.obj "D:\Tests\MyDLL\gpu_compute.cu"

A: The error was caused by not yet released Driver Version 465.21 shipped with the Windows Insider edition. Rolling back to current 461.40 solved this.

redpajama_set_name: RedPajamaStackExchange


I was recently presented with the opportunity to design another pattern for our friends at AllFreeKnitting, complete with this Lion Brand Sock-Ease yarn. And, long story short, this is what I came up with - a dainty color pattern that completes a clean design. I also knit one of these bad boys on 9" circulars, which I quite enjoyed (especially with this eensy weensy yarn). Anyway, you'll have to visit AllFreeKnitting to find the pattern for now (link below), but you can find all kinds of pictures right here in the meantime!
A closer view of these little snockerinos.
I know, I know - you really just want the pattern, huh? Well feast your eyes on the photos I've included below and then click through to find out how to make these sweet little guys!
It's been days, at least, since I last mentioned my obsession with Malabrigo yarn. Therefore I'll this opportunity to say it again: I am obsessed with Malabrigo yarn. Especially this lovely Arroyo fiber, a sport-weight superwash that, for me at least, knit up slightly smaller than gauge. And speaking of gauge, these socks are designed for a sport-weight fiber, but you will, as always with something as finicky as socks, want to check your gauge. And remember that your dpn knitting will probably look better on a thicker fiber knit with smaller needles than the opposite, so I would definitely try to gauge down a slightly larger fiber before I'd try to gauge up a finer fiber. Am I making any sense here? Feel free to hit me up with questions in the comments; in the meantime, let's get to the pattern.
A better view of the ol' snockerinos.
Not that anybody calls them that.
So let's make some socks! Of course, before we get to that, I should mention that I'm using Ann Budd's delightful Getting Started Knitting Socks (Getting Started series) for the sizing and basic design elements of these socks, as well as a couple of Ribbon Stitch cables from page 245 of Barbara G. Walker's A Treasury of Knitting Patterns for the stitch pattern. And now that that's covered, let's actually make those socks!


text:
Q: Fill a PDF with the input details obtained from a react app I am building a React.js application which takes some input like name, age, email etc from the users and I need to fill these data into a Form 11 PDF and enable users to download the filled PDF. So basically a slight automation software for form 11. So far I have obtained the data from users and have stored it in variables using the useState hook. How can I fill these data onto the respective spaces in a Form 11 PDF. Welp!

A: pdf-lib is an option. Its very very simple to implement.
Fill form official example: https://pdf-lib.js.org/#fill-form
Another option is pdfform.js


text:
S&P raises outlook on Connecticut's general obligation bonds credit rating
James Comtois
Standard & Poor's raised its outlook on Connecticut's general obligation bonds credit rating to "positive" from "stable," and affirmed the state's outstanding bond rating at an A, said a news release issued by Connecticut Treasurer Shawn T. Wooden's office.
This is the first positive outlook or credit rating upgrade for Connecticut's general obligation bonds since 2001.
This action comes nearly a week after Mr. Wooden, Gov. Ned Lamont and Office of Policy and Management Secretary Melissa McCaw made presentations in Hartford to all four national credit rating agencies on the state's improving economy, fiscal controls on bonding in the Mr. Lamont's proposed budget, increases in the budget reserve fund and common cash pool, and a plan to restructure the $18.7 billion state Teachers' Retirement Fund.
"This positive change in Connecticut's credit outlook is another significant step in the right direction that is drawing notice on a national level," Mr. Wooden said in the news release. "The next step is to follow through on plans to address our current economic challenges and continue building a stable foundation for future growth and financial sustainability."
The state is preparing to sell $850 million of general obligation bonds during the last week of March.
Public plans surf wave of reforms in aftermath of crisis
Connecticut governor proposes reforms to state teachers fund in conjunction wit…
Connecticut treasurer on mission to maximize returns, minimize risks
States consider asset transfers as way to shore up plan funding
Connecticut eyes $125 million commitment to buyout fund
Kroll Bond Rating Agency upgrades outlook on New Jersey to positive
Milken panel sees solid demand for hedge funds despite lower returns
Fallen angel ETFs hit $10 billion in assets


At Indie Etc, we take pride in offering sterling silver options for every silver plated necklace we can create. There is a lot to consider however when upgrading to sterling silver. Though it will create a longer lasting necklace, and creates a more beautiful and one of a kind piece, the necklace will have to be worn with care. By following the tips and information below, we hope you too can have a one of a kind keepsake that you will continue to love.
Over time, any sterling silver piece exposed to air will begin to tarnish. Most sterling silver pieces are 92.5% silver and 7.5% other metals such as zinc, platinum, but mostly copper. The copper is what causes most tarnish in the sterling silver. The copper causes the tarnishing process when it reacts to moisture and sulfurs in the air. Sterling silver seems to tarnish a lot faster in areas with high humidity and air pollution. Chemicals such as perfume, hairspray, and body lotions can drastically speed up the tarnishing process.
When your sterling silver jewelry is not being worn, it is best to keep it in a cool, dark place away from sources of sunlight, heat, and moisture. At Indie Etc, all of our sterling silver necklaces are shipped in a box with silica gel moisture absorbers, and placed into a ziploc bag. This makes for the perfect way to store your jewelry when not being worn. Another great item to use while storing is a small strip of anti-tarnish paper that can be placed in the bag along with the jewelry.
When wearing your sterling silver pieces, it is best to not wear in showers, swimming pools, hot tubs, or any place where the item may get wet. Humidity and moisture can start the tarnishing process a lot faster, than if kept dry.
If tarnishing starts to appear on your necklace, it can be cleaned with a polishing cloth. If a polishing cloth can not remove all of the tarnish, start with the steps below. These steps are for a completely sterling piece, and NOT for gemstones or pearls or other objects that may be adorned on the necklace.
Wash the necklace in warm water with a few drops of mild dish soap. Immerse the sterling silver piece in the water and gently hand wash.
A cotton swab can be used for corners and crevices.
If more abrasive cleaning is needed, a very soft baby toothbrush can be used.
Thoroughly rinse your necklace, and be sure to completely dry before storing, as moisture will cause tarnishing to return.
Do not use harsh chemicals such as bleach, acetone, etc. They will ruin the surface of your jewelry.
Do not use toothpaste or baking soda to clean, as it can scratch your jewelry.


Tech Review – There are many options and specifications when choosing a gaming monitor—the same goes for other gaming equipment, but monitors require you to carefully consider the visuals you're going to see while playing. For starters, you need a gaming monitor that came from a popular brand with a solid reputation. You can never go wrong with trusted brands.
Today's episode of Tipify Gaming Equipment series introduces you to Amazon's featured brand of the week: LG, and its most popular monitor to date: LG 34UC80-B 34-Inch.
The monitor is available on Amazon at $549.99 USD. According to first-hand reviews, it's currently one of the cheapest and most impressive monitors you can find online, and it is actually ideal for both work and play. It garnered an impressive 4.5 out of 5 stars reviews from almost 300 customers on Amazon alone—buyers from other sites and physical websites are as equally impressed.
LG 34UC80-B 34-Inch is frequently bought together with AmazonBasics HL-007306 High-Speed HDMI Cable worth $6.99 USD to make the monitor compatible with other viewing devices. It rivals monitors from other trusted brands like the Acer R240HY bidx 23.8-Inch and Dell UltraSharp U3415W 34-Inch.
The LG 34UC80-B 34-Inch has an In-Plane Switching (IPS) panel. This means that the liquid crystals inside are parallel to produce color—allowing the resolution to retain the original color of the graphics regardless of the viewing angles. The wide curve of the screen carries a -5°/20° tilt, a maximum of 120mm height adjustment, and VESA mount support. You can easily adjust the mount with a simple press and click to find the most comfortable viewing angle.
For connectivity with other devices or gaming accessories, there are two HDMI 2.0 ports, one DisplayPort 1.2, one headphone jack, and a pair of USB 3.0 port surrounding the monitor's body.
The 3440 X 1440 UltraWide QHD display gives an impressive and sharp picture quality. More than that, its pixel area is roughly 1.8 times larger than most monitors with UltraWide Full HD 21:9 ratio and about 2.4 times larger than monitors with Full HD 16:9 ratio.
On top of the impressive display, you can also find other features only LG products can simultaneously possess: 99% sRGB spectrum, on-screen control technology, screen split feature, AMD FreeSync Technology, and game mode customization (2 FPS mode and one RTS pre-set mode).


text:
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Paul Emery1,2,
Jiří Vencovský3,
Anna Sylwestrzak4,
Piotr Leszczyński5,
Wieslawa Porawska6,
Barbara Stasiuk7,
Joanna Hilt8,
Zdenka Mosterova9,
Soo Yeon Cheong10,
Jeehoon Ghil10
1Arthritis Research, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
3Rheumatology, Institute of Rheumatology, Prague, Czech Republic
4Rheumatology, NZOZ Medica Pro Familia Sp. z o.o., Warsaw, Poland
5Rheumatology, Poznan University of Medical Sciences, Poznan, Poland
6Rheumatology, Poznanski Osrodek Medyczny NOVAMED, Pultusk, Poland
7Rheumatology, Medicome Sp. z o.o, Oswiecim, Poland
8Rheumatology, Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna, Bialystok, Poland
9Rheumatology, Revmacentrum MUDr. Mostera sro, Brno, Czech Republic
10Clinical Sciences Division, Samsung Bioepis Co., Ltd., Incheon, Republic of Korea
Correspondence to Professor Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK; p.emery{at}leeds.ac.uk
Objectives SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and immunogenicity when continuing SB4 versus switching from ETN to SB4.
Methods In the randomised, double-blind phase, patients received weekly subcutaneous administration of 50 mg SB4 or ETN with background methotrexate for up to 52 weeks. Patients in the Czech Republic and Poland who completed the 52-week visit were enrolled in the open-label extension period and received SB4 for 48 additional weeks. Efficacy, safety and immunogenicity were assessed up to week 100.
Results Of 245 patients entering the extension period, 126 continued to receive SB4 (SB4/SB4) and 119 switched to SB4 (ETN/SB4). American College of Rheumatology (ACR) response rates were sustained and comparable between SB4/SB4 and ETN/SB4 with ACR20 response rates at week 100 of 77.9% and 79.1%, respectively. Other efficacy results, including radiographic progression, were also comparable between the groups. After week 52, rates of treatment-emergent adverse events were 47.6% (SB4/SB4) and 48.7% (ETN/SB4); one patient/group developed non-neutralising antidrug antibodies. No cases of active tuberculosis or injection-site reactions were reported during the extension period. One patient (SB4/SB4) died of hepatic cancer.
Conclusions SB4 was effective and well tolerated over 2 years in patients with RA. Efficacy, safety and immunogenicity were comparable between the SB4/SB4 and ETN/SB4 groups, showing no risk associated with switching patients from ETN to SB4.
Trial registration number NCT01895309; 2012-005026-30
anti-TNF
DMARDs (biologic)
TNF-alpha
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
The tumour necrosis factor inhibitor etanercept was the first approved biologic disease-modifying antirheumatic drug and allowed for a major advance in the treatment of rheumatoid arthritis (RA).1 Eighteen years since its approval, etanercept continues to play a key role in RA management, having demonstrated efficacy and a manageable safety profile in both clinical trial and real-world settings.1 Other current indications for etanercept include juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (European Union only), plaque psoriasis and paediatric psoriasis (USA only).2 3
SB4 (Benepali, Samsung Bioepis UK Limited, Surrey, UK; Brenzys, Samsung Bioepis, Republic of Korea) is a biosimilar of reference etanercept (ETN). The structural, physicochemical and biological quality attributes of SB4 have been shown to be highly similar to ETN in a comprehensive comparability exercise designed as part of the European Medicines Agency's rigorous approval pathway.4 A phase 1 study in healthy subjects demonstrated pharmacokinetic equivalence between SB4 and ETN5 ; a phase 3 study (NCT01895309; EudraCT 2012-005026-30) in patients with moderate to severe RA despite treatment with methotrexate (MTX) demonstrated equivalent efficacy in terms of American College of Rheumatology 20% response rate (ACR20) at the 24-week interim analysis (SB4, 78.1%; ETN, 80.3%)6 and at week 52 (SB4, 80.8%; ETN, 81.5%).7 Safety was generally comparable between SB4 and ETN.6 7
SB4 has been approved for treatment of RA, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and plaque psoriasis in the European Union.8 9 However, an important consideration for prescribing physicians is whether switching from ETN to SB4, which may occur in clinical practice, can be achieved without detriment to safety and efficacy. We analysed data from the open-label extension period of the phase 3 study to evaluate the efficacy, safety and immunogenicity of continuing SB4 (SB4/SB4) versus switching from ETN to SB4 (ETN/SB4). Long-term safety and efficacy were assessed up to week 100.
Study design and patients
Patients with moderate to severe RA despite treatment with MTX were eligible to enrol in this phase 3, randomised, double-blind, multicentre study, which included an open-label extension period. Detailed patient inclusion/exclusion criteria were previously published.6 During the double-blind period, patients were randomised 1:1 to receive subcutaneous SB4 50 mg or ETN 50 mg once weekly for 52 weeks. Patients in the Czech Republic or Poland who completed the scheduled 52-week visit were enrolled in the open-label, single-arm extension period. During the extension period, patients from the SB4 group continued to receive SB4 (SB4/SB4), and patients from the ETN group switched to SB4 50 mg (ETN/SB4) once weekly for an additional 48 weeks. All patients took a stable dose of MTX (10–25 mg/week) from 4 weeks before screening until the end-of-treatment visit for the extension period. For patients who entered the extension period, efficacy was assessed at weeks 52, 76 and 100, and safety was assessed at all visits during treatment and at 4 weeks after treatment (or after the early termination visit).
Efficacy endpoints for the extension period included ACR20/50/70 response (≥20%/50%/70% improvement, respectively, from baseline in ACR response criteria), European League Against Rheumatism (EULAR) response and disease activity score based on a 28-joint count (DAS28). Physical function was assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI). For patients who entered the extension period, radiographs of the hands and feet obtained at weeks 0, 52 and 100 were evaluated by a single reader to determine the modified Total Sharp Score (mTSS), which is the sum of the joint erosion and joint space narrowing (JSN) scores.10 Post hoc assessments included the proportions of patients achieving low disease activity (LDA) and remission based on the Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and DAS28 and the proportions achieving Boolean-based remission (defined as ≤1 swollen and ≤1 tender joint, C-reactive protein ≤1 mg/dL and patient global visual analogue scale score ≤1 using a 0–10 scale). Safety endpoints included the incidence of treatment-emergent adverse events (TEAEs) and adverse events (AEs) of special interest (serious infections and active tuberculosis). Immunogenicity was assessed by determining the incidence of antidrug antibodies (ADAs) and neutralising antibodies; ADAs were detected in serum samples using an electrochemiluminescence bridging assay (Meso Scale Discovery, Maryland, USA), double-antigen format with acid dissociation and neutralising antibodies were measured using a competitive ligand-binding assay.6
All data were analysed descriptively. Efficacy and safety data were analysed in the extended population, which comprised all patients who provided informed consent for the open-label extension period and received ≥1 dose of study medication in the open-label extension period. Efficacy data obtained up to week 52 were analysed retrospectively in this population. No imputation was made for missing data. Analyses were performed using SAS software, V.9.2 or higher (SAS Institute, Cary, North Carolina, USA).
A total of 245 patients, including 126 who continued on SB4 and 119 who switched to SB4 from ETN, enrolled in the extension period. All patients received ≥1 dose of study drug during the extension period and were included in this analysis. Patient disposition is shown in figure 1; 94.7% of patients (232/245) who entered the extension period completed 100 weeks of treatment, with 5.6% of patients in the SB4/SB4 group and 5.0% of patients in the ETN/SB4 group withdrawing before week 100. Patient demographic and clinical characteristics were well balanced between the two groups (table 1).
Patient baseline demographics and disease characteristics at baseline and week 52 (extended population)
Patient disposition. AE, adverse event; ETN, reference etanercept.
ACR responses were comparable between the SB4/SB4 and ETN/SB4 groups and were maintained from weeks 52 through 100, with 79.2%/52.0%/38.4% and 82.4%/53.8%/32.8% of patients achieving ACR20/50/70 in each group, respectively, at week 52% and 77.9%/59.8%/42.6% and 79.1%/60.9%/41.7% of patients achieving ACR20/50/70 in each group, respectively, at week 100 (figure 2). ACR responses were also comparable between the two groups in the retrospective analysis of this population during the initial 52-week treatment period. Other efficacy results at week 100 are shown in table 2. At this time point, the proportion of patients who had moderate or good EULAR responses; the proportion who achieved LDA and remission based on DAS28, SDAI or CDAI criteria and the proportion who achieved Boolean-based remission were comparable between the SB4/SB4 and ETN/SB4 groups. Further, throughout the study, DAS28, SDAI, CDAI and HAQ-DI scores were also comparable between the two groups (see figure in the online supplementary material 1). The main factor driving the improvement in DAS28 score was the reduction in swollen and tender joint counts; these components demonstrated the largest percentage improvements from baseline during the extension period. At week 100, radiographic progression was comparable and minimal (figure 3), with mean (SD) change from baseline mTSS values of 0.48 (4.053) for the SB4/SB4 group and 1.00 (5.563) for the ETN/SB4 group (table 2). Summary of structural joint damage for each visit can be found in table S1 in the online supplementary material 1.
Supplementary material 1
[SP1.docx]
Efficacy results at week 100 (extended population)
American College of Rheumatology (ACR) response rates up to week 100 (extended population). ACR20/50/70=American College of Rheumatology 20%/50%/70% response criteria; ETN, reference etanercept.
Cumulative probability of mTSS change from baseline at week 100 (extended population). Data based on patients with available radiographic assessment results at each visit. ETN, reference etanercept; mTSS, modified Total Sharp Score.
Safety after week 52 was generally comparable between the SB4/SB4 and ETN/SB4 groups (table 3). This extension study was not adequately powered to showsimilar safety and imbalance might be expected as shown in the incidence of serious TEAEs, RA, viral infection, laryngitis and hypertension. Serious infection was reported in one patient in each treatment group, and there were no reports of active tuberculosis. Also during the extension period, no injection-site reactions were reported. One patient in the SB4/SB4 group died of hepatic cancer, which was considered to be related to the study drug. One patient in each treatment group developed non-neutralising ADAs after week 52 (see table S2 in the online supplementary material 1). Both patients had a low titre, and the ADAs did not affect efficacy. The patient in the SB4/SB4 group tested positive at week 100 with a titre of 1 and achieved an ACR50 response at week 100. The patient from the ETN/SB4 group tested positive at week 76 with a titre of <1 and achieved an ACR70 response at week 100.
Safety after week 52 (extended population)
This open-label extension period of a phase 3, randomised, double-blind study evaluated the long-term efficacy, safety and immunogenicity of SB4 in patients with moderate to severe RA despite MTX treatment and compared outcomes between patients who continued SB4 (n=126) and those who switched from ETN to SB4 (n=119). Results showed SB4 to be effective and well tolerated over 2 years. In patients who switched from ETN to SB4, comparable efficacy to the SB4/SB4 group was observed, with no new safety signals identified.
Among the patients entering the extension period, 94.4% in the SB4/SB4 group and 95.0% in the ETN/SB4 group completed an additional 48 weeks of SB4 treatment. The discontinuation rate due to lack of efficacy or TEAEs was very low, which suggests the long-term tolerability of SB4 treatment.
Efficacy outcomes in the extended population were comparable between the SB4/SB4 and ETN/SB4 groups at all visits up to week 100, sustained from weeks 52 to 100 and unaffected by switching. Comparable inhibition of radiographic progression was previously reported after 52 weeks of treatment with SB4 or ETN (mean change in mTSS: 0.45 for SB4 vs 0.74 for ETN).7 In both groups, continued inhibition of radiographic progression was observed with an additional year of SB4 treatment, with mean changes from baseline in joint space narrowing and joint erosion of <1. This is consistent with historical results from randomised studies of etanercept with or without MTX in patients with RA.11–13 Two-year radiographic findings in patients with early RA continuing ETN+MTX therapy from year 1 showed a mean Sharp/van der Heijde score change of −0.02 and an improvement in mean 28-swollen joint count from 1.7 to 1.3.11 Similarly, 2-year data from the Canadian Methotrexate and Etanercept Outcome study showed that patients continuing ETN+MTX therapy after the first 6 months had mean changes from baseline in mTSS and JSN of 0.0 at month 24 and those switching to ETN monotherapy had mean changes from baseline in mTSS and JSN of <1.12 Lastly, the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) demonstrated mean changes from baseline in mTSS, joint erosion scores and JSN of <1 at years, 1, 2 and 3 of treatment with ETN+MTX.13
In the extension period, SB4 demonstrated a safety profile similar to that observed in the pivotal etanercept trials.11–13 There were no reports of active tuberculosis or injection-site reactions. One patient in each group reported a serious infection and one patient in the SB4/SB4 group died from hepatic cancer. After week 52, one patient in each group developed non-neutralising ADAs. The low incidence of non-neutralising ADAs observed in the study was expected given the low rates reported in short-term and long-term studies of etanercept-treated patients with RA (0%–6%).14–16 The ADAs developed prior to switching did not affect the efficacy or safety of SB4 in the ETN/SB4 group.
Results from this extended-period switching study showed maintenance of response after switching from ETN to SB4 with no newly identified safety issues (eg, no increase in immunogenicity or immune-related TEAEs of anaphylaxis, hypersensitivity or injection-site reactions). In extensions of PLANETRA (Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients)17 and PLANETAS (Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS patients)18 which had similar study designs with the present study, switching from reference infliximab to the biosimilar infliximab CT-P13 was not associated with diminished efficacy or change in safety profile. These results are further corroborated by findings from the randomised, non-inferiority NOR-SWITCH study which demonstrated that switching to CT-P13 is not inferior to continued treatment with reference infliximab.19 In addition, data from the DANBIO registry where a nationwide switch took place, disease activity was not affected by the non-medical switch from the reference infliximab or ETN to CT-P13 or SB4, respectively.20 21 Observations from these studies provide data relevant to clinical practice and support switching of reference products to biosimilars for non-medical reasons.
A retrospective analysis of our data was conducted for any potential anaphylaxis cases using related AEs (eg, pruritus, flushing, dyspnoea, hypotonia, syncope, incontinence, vomiting) and blood pressure (systolic blood pressure <90 mm Hg or >30% decrease from baseline), as defined in the National Institute of Allergy and Infectious Diseases/Food Allergy Anaphylaxis Network criteria.22 No cases of potential anaphylaxis were identified based on this analysis.
The open-label nature of the extension period is a study limitation. Because patients were required to have completed the 52-week visit of the randomised, double-blind period in order to enrol in the extension, there was the potential for selection bias. However, baseline demographic and clinical characteristics were well balanced between the treatment groups and were representative of those in the core study. Moreover, disease activity at week 52 for patients who enrolled in the extension period was comparable with that of patients who did not enrol in the extension period (see table S3 in the online supplementary material 1), suggesting no selection bias towards patients who responded well to treatment. This switching study was designed to evaluate approximately 100 patients in each group to allow detection of an increase in the risk for injection site reactions to 1% or more. Therefore, the two countries with the largest number of enrolled patients (Poland and the Czech Republic) were selected to participate in the extension period. Although the extension period was not designed to compare equivalence statistically, it provides valuable data on switching from ETN to SB4 in patients with RA.
SB4 was well tolerated and effective over 2 years in patients with RA. Switching from ETN to SB4 was not associated with treatment-emergent issues such as loss of efficacy or increases in TEAEs or immunogenicity. Postmarketing surveillance and registry studies are ongoing to monitor the efficacy and safety of SB4 in various indications.
The authors thank the patients who were involved in this extension study, the study personnel who made this work possible and the study investigators. From the Czech Republic, this included L Podrazilova, M Sedlackova, G Simkova, H Brabcova, Z Urbanova, J Kopackova, P Vitek, and Z Stejfova. From Poland, this included I Janecka, A Rychlewska-Hanczewska, A Zielinska, S Daniluk, J Glogowska-Szelag, B Sliwowska, M Rell-Bakalarsk and B Grabowicz-Waśko.
Editorial support for development of this manuscript was provided by Nicole Strangman, PhD, of C4 MedSolutions, LLC (Yardley, Pennsylvania, USA), a CHC Group company and funded by Samsung Bioepis Co., Ltd.
Results included in this manuscript have been previously presented at the 2016 EULAR Congress and 2016 ACR/ARHP Annual Meeting.
Scott LJ
. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 2014;74:1379–410.doi:10.1007/s40265-014-0258-9
Enbrel®. Etanercept. Thousand Oaks, CA: Immunex Corporation, 2016.
Enbrel® (etanercept). Product characteristics 2016.
Cho IH,
Lee N,
Song D, et al
. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs 2016;8:1136–55.doi:10.1080/19420862.2016.1193659
Lee YJ,
Shin D,
Kim Y, et al
. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel) in healthy subjects. Br J Clin Pharmacol 2016;82:64–73.doi:10.1111/bcp.12929
Emery P,
Vencovský J,
Sylwestrzak A, et al
. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:51–7.doi:10.1136/annrheumdis-2015-207588
Vencovsky J,
Sylwestrzak A,
Leszczynski P, et al
. A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results) [abstract]. Arthritis Rheumatol 2015;67:2444–6.
Benepali®(etanercept). Product characteristics 2016.
Brenzys™ (etanercept). Product monograph 2016.
van der Heijde D
. How to read radiographs according to the sharp/van der Heijde method. J Rheumatol 2000;27:261–3.
Breedveld F,
van der Heijde D, et al
. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674–82.doi:10.1002/art.27268
Keystone EC,
Pope JE,
Thorne JC, et al
. Two-year radiographic and clinical outcomes from the Canadian methotrexate and etanercept outcome study in patients with rheumatoid arthritis. Rheumatology 2016;55:327–34.doi:10.1093/rheumatology/kev338
Klareskog L,
. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928–39.doi:10.1002/art.23141
Dore RK,
Mathews S,
Schechtman J, et al
. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40–6.
Gaubitz M,
Rodríguez-Valverde V, et al
. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238–47.
Weinblatt ME,
Schiff MH,
Ruderman EM, et al
. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008;58:1921–30.doi:10.1002/art.23493
Yoo DH,
Prodanovic N,
Jaworski J, et al
. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355–63.doi:10.1136/annrheumdis-2015-208786
Park W,
Miranda P, et al
. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346–54.doi:10.1136/annrheumdis-2015-208783
Jørgensen KK,
Olsen IC,
Goll GL, et al
. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304–16.doi:10.1016/S0140-6736(17)30068-5
Glintborg B,
Sørensen IJ,
Loft AG, et al
. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76:1426–31.doi:10.1136/annrheumdis-2016-210742
. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the Danbio registry. Ann Rheum Dis 2017;76:553.
Sampson HA,
Muñoz-Furlong A,
Campbell RL, et al
. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391–7.doi:10.1016/j.jaci.2005.12.1303
Contributors PE, SYC, and JG contributed to the study conception and design, analysis and interpretation of data and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JV, AS, PL, WP, BS, JH and ZM contributed to the acquisition of data. All the authors equally contributed to the drafting the manuscript and revising it critically for important intellectual content, final approval of the version published.
Funding This study was funded by Samsung Bioepis Co., Ltd.
Competing interests All authors received funding for clinical research from Samsung Bioepis. PE received consulting fees; JV, AS, PL, WP, BS, JH, and ZM received research grants and SYC and JG are full-time employee of Samsung Bioepis. In addition, PE reports receiving grant/research support from AbbVie and Pfizer and consultancy fees from AbbVie, Bristol-Myers Squibb, Pfizer, UCB, Merck Sharp & Dohme, Roche, Novartis, Takeda and Lilly; JV served on speakers bureaus for UCB, Pfizer, AbbVie and Merck Sharp & Dohme; PL received grant/research support from Roche, Merck Sharp & Dohme, Janssen, Novo-Nordisk, UCB, Pfizer, Novartis, GlaxoSmithKline, Bristol-Myers Squibb, served as paid instructor for Novo-Nordisk and served on speakers bureaus for Merck Sharp & Dohme, UCB, Roche and Amgen.
Patient consent Obtained.
Ethics approval This study was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical practice guidelines. Protocols were reviewed and approved by the independent ethics committee or institutional review board for each study centre. All patients provided written informed consent.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/


text: Hello {{name}}, I think you are {{age}} old?

redpajama_set_name: RedPajamaGithub